Discussing radiotherapy, AAA and CEO leadership with Riccardo Canevari: CEO of Radiopharm Theranostics
In this episode, Charles talks with Riccardo Canevari, the managing director and CEO of Radiopharm Theranostics, a company that is innovating the way we see cancer. They talked about his leadership journey in transitioning from leading 110k employees to a 3-man startup team. He also discusses launching innovative cancer treatments such as Luziterra and BluVicto and the challenges of selling them. He also highlights the importance of mission-driven work in biotech and the promise of radiopharmaceuticals in cancer treatment.
Here's what you are in for:
00:00 Ricardo's Journey From Milan to Pharma Leader
00:19 Family's Influence in Early Life
03:25 Ricardo's Career Path from Chemistry to Pharma
05:38 Highs and Lows in Pharma Industry
05:51 Leadership Lessons
10:27 Taking the new role as the head of Radio Pharm
17:59 Building a 3-man start up team
30:24 Reflecting on Leadership and Advancement
35:41 The Future of Radiotherapy
About Riccardo Canevari
Riccardo is an experienced leader in specialty pharma, cancer care, and radiopharmaceuticals. He served as the Chief Commercial Officer at Advanced Accelerator Applications, a leading company owned by Novartis. There, he led commercial strategies in around 20 countries. His main focus was on expanding the market for Lutathera and preparing for the launch of Lu-PSMA 617 to treat advanced prostate cancer. Before this, Riccardo held top positions at Novartis Oncology. He oversaw the successful introduction of breast cancer drugs like KISQALI and PIQRAY. He also gained extensive experience from different roles at Novartis Pharma and Ethicon/Johnson & Johnson.
Connect with Riccardo:
LinkedIn: https://www.linkedin.com/in/riccardo-canevari-7239931/
Website: https://www.radiopharmtheranostics.com/
About Charles
Charles Spence leads Discera, a leading recruitment firm specializing in the biopharma industry.
He graduated with a biomedical degree, has worked in hospitals (including translation work in Seoul, South Korea), and also spent years doing diabetes research. After doing research and travel, a career in business and science felt the most appropriate.
In 2023, Charles decided to launch his firm - Discera Search. A firm committed to solving the
biggest talent needs of Early clinical stage SME biotechs on the East Coast and DACH.
Connect with Charles:
LinkedIn:https://www.linkedin.com/in/charles-spence-clinical/
